NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $22,692.00 in Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 3,720 shares of the firm’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $6.10, for a total value of $22,692.00. Following the completion of the transaction, the insider now owns 5,499,065 shares of the company’s stock, valued at approximately $33,544,296.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Friday, October 18th, Ltd. Kck sold 4,878 shares of NeuroPace stock. The stock was sold at an average price of $6.29, for a total transaction of $30,682.62.
• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The shares were sold at an average price of $6.57, for a total transaction of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The stock was sold at an average price of $6.54, for a total transaction of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The shares were sold at an average price of $6.35, for a total transaction of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The shares were sold at an average price of $6.10, for a total value of $19,050.30.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The shares were sold at an average price of $6.66, for a total value of $32,700.60.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The shares were sold at an average price of $6.97, for a total value of $23,126.46.

NeuroPace Stock Performance

NASDAQ NPCE opened at $6.04 on Friday. The company has a debt-to-equity ratio of 5.97, a current ratio of 6.37 and a quick ratio of 5.47. The stock’s 50 day simple moving average is $7.00 and its 200-day simple moving average is $8.23. The company has a market cap of $176.37 million, a PE ratio of -5.54 and a beta of 1.78. NeuroPace, Inc. has a 1-year low of $5.66 and a 1-year high of $18.15.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The company had revenue of $19.26 million for the quarter, compared to analyst estimates of $18.30 million. During the same quarter last year, the firm posted ($0.36) EPS. The firm’s revenue for the quarter was up 16.6% on a year-over-year basis. As a group, equities research analysts anticipate that NeuroPace, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Trading of NeuroPace

Several large investors have recently bought and sold shares of NPCE. Vanguard Group Inc. lifted its stake in NeuroPace by 18.3% in the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock worth $6,450,000 after purchasing an additional 75,512 shares in the last quarter. Acadian Asset Management LLC purchased a new position in NeuroPace during the first quarter worth approximately $621,000. Hillsdale Investment Management Inc. acquired a new position in NeuroPace during the first quarter worth $155,000. Bank of New York Mellon Corp purchased a new stake in NeuroPace in the 2nd quarter valued at $257,000. Finally, Financial Advocates Investment Management grew its holdings in NeuroPace by 50.0% in the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after buying an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Morgan Stanley decreased their target price on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Wells Fargo & Company lowered their target price on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 price target on shares of NeuroPace in a research note on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, NeuroPace currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.